Latest Breaking News On - Ted human effector cell relocation phase - Page 1 : comparemela.com

CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting

Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"

Mccormick placeUnited statesPhil lhuilierIgnacio melero bermejoCatalym gmbAlison opalkoTrophic communicationsOncology congressAmerican society of clinical oncologyTed human effector cell relocation phaseAmerican societyClinical oncologyAnnual meetingGrowth differentiationPresentation detailsUniversidad de navarra

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ignacio meleroPhil lhuillierCatalym gmbOncology congressDepartment of immunologyInternational coordinating investigator profEuropean society for medical oncologyTrophic communicationsObjective response ratesTed human effector cell relocation phaseEuropean societyMedical oncologyImmuno oncology congressGrowth differentiationInternational coordinating investigatorUniversidad de navarra

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Christine schuberth wagnerCalaym gdfatherAlison opalkoPhil lhuilierCatalym gmbTrophic communicationsNature communicationsBusiness wireGrowth differentiationChief scientific officerTed human effector cell relocationTed human effector cell relocation phasePhill huilierDie experten

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

Oral presentation highlights first data from the GDFATHER-2a trial demonstrating lasting and confirmed responses (as per RECIST criteria) following treatment with visugromab and the anti-PD-1 inhibitor

Mecklenburg vorpommernUnited statesPhil lhuilierIgnacio melero bermejoPhil lhuillierStefan klotterCatalym gmbInternational coordinating investigator profAmerican society of clinical oncologyTrophic communicationsTed human effector cell relocation phaseAmerican societyClinical oncologyAnnual meetingGrowth differentiationEugen leo

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCatalym gmbPhil lhuilierIgnacio melero bermejoTrophic communicationsAmerican society of clinical oncologyTed human effector cell relocation phaseAmerican societyClinical oncologyAnnual meetingClinica universidad de navarraArie crown theaterMccormick placeLive streamTed human effectorRelocation phase